NONOF:OTCMKTS
Novo Nordisk A/S
36,83 USD
arrow_downward
-1,46%(-0,55) 1D
2-окт., 15:05:12 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NONOF...
Open
37,95 USD
High
38,44 USD
Low
36,69 USD
Mkt. cap
128,25 млд
Avg. vol.
134,38 миң
Volume
14,23 миң
52-wk high
64,75 USD
52-wk low
34,00 USD
Beta
0,63
Shares outstanding
3,39 млд
No. of employees
67 миң
Open
37,95 USD
High
38,44 USD
Low
36,69 USD
Mkt. cap
128,25 млд
Avg. vol.
134,38 миң
Volume
14,23 миң
52-wk high
64,75 USD
52-wk low
34,00 USD
Beta
0,63
Shares outstanding
3,39 млд
No. of employees
67 миң
News stories
From web sources and news partners
AD HOC NEWS
·
2 саат мурун
Novo Nordisk stock after-hours at EUR 33.14: minus 0.48 percent versus prior close
TipRanks
·
2 саат мурун
Novo Nordisk Tests Zenagamtide Dosing to Sharpen Its Obesity Drug Pipeline
The Motley Fool
·
3 саат мурун
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Simply Wall Street
·
15 саат мурун
Novo Nordisk (NVO) Stock Looks Reasonable Given Uncertain Long Term Earnings
Profile
Novo is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark's domestic economy, and it became the highest valued company in Europe. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees66,7 миң
Founded1923-ж., 21-дек.
HeadquartersBagsværd, Capital Region of Denmark, Дания
SectorPharmaceutical industry
Websitenovonordisk.com